SNY

Sanofi ADR (SNY) | Rumor.io

Sanofi

SNY

Attention (50-day avg)0%

Attention rank (50-day avg)#833

Bullish sentiment (50-day avg)94%

Price to earnings ratio22.3

Market capitalization98.7B

Earnings per share1.84

Dividend yield (TTM)23.5%

Revenue (annual)46.7B

Net income (annual)7.9B

Social

What share of all stock conversation is about SNY?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% -0.01	0% +0	0% 0	0.01% 0

Aug 17

A financial analyst purchased Sanofi shares based on technical analysis, but now questions the decision after reevaluating the analysis.
A job posting at Sanofi (CIC) is announced, seeking a head for the COVID vaccine portfolio, including combination vaccines with Nuvaxovid.
The analyst's Sanofi graph is different when using dividend reinvestment, and they are asked why they choose not to include it.

Generated by AI

Sentiment

Of the messages about SNY that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	0% -100	92.17% -7.83	84.34% -11.46	83.09% +2.73
Bearish	100% new	7.83% new	15.66% +11.46	16.91% -2.73

Bullish· Jan 15

Sanofi is reportedly preparing a sweeter takeover offer for Ocular Therapeutix, which could lead to a higher price for the asset.
The asset's strong ophthalmology pipeline, including the AXPAXLI Ph3 data expected in Q1 2026, adds a significant catalyst layer to the potential takeover.
The expected takeover and strong pipeline make the asset's current price of under $11 a potential buying opportunity.

Bearish· Sep 4

$SNY's amlitelimab failed to meet expectations in its Phase 3 trial, with efficacy falling short of Dupixent's benchmark.
The disappointing trial results led to a significant drop in Sanofi's stock price, with investors questioning the company's pipeline post-2031 patent expiry.
The failure of amlitelimab raises concerns about Sanofi's ability to offset Dupixent's looming patent expiry, which could have a major impact on the company's sales and revenue.

Generated by AI

Topics

Of the messages about SNY that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	64.84%	64.67%	18.05%
Macro	—	33.59%	15.82%	37.26%
Earnings	—	0%	8.26%	1.24%
Technical Analysis	—	0%	0.7%	3.09%
Analysts	—	1.56%	10.54%	38.97%
Controversies	—	0%	0%	1.4%

Earnings· Oct 27

Sanofi reported Q3 earnings of $2.55 per share, missing the FactSet consensus of $1.30, and saw revenues fall 4.1% year/year to $11.96 billion.
The company reaffirmed guidance for FY23, seeing EPS growth in the mid single-digits, but warned that increased investments in R&D and a tax-rate change will cause 2024 earnings to fall from 2023 levels.
Sanofi's shares sank 17% after the earnings report, with the company also planning to spin off its consumer health division and bring it to the stock exchange.

Analysts· Apr 7

HSBC Securities downgraded Sanofi (SNY) to "Reduce" from "Hold".
Argus initiated coverage of Sanofi (SNY) with a "Buy" rating.
Raymond James Trust N.A. increased its stake in Sanofi (SNY).

Announcements· Mar 4

Sanofi has entered into an exclusive global licensing agreement with Sino Biopharmaceutical for the development, manufacturing, and commercialization of rovadicitinib, a dual JAK/ROCK inhibitor.
Sanofi will pay up to $1.53B for global rights to a first-in-class JAK/ROCK inhibitor from Sino Biopharmaceutical, with the asset already approved in China for myelofibrosis and in Phase 3 for cGVHD.
Sanofi has secured a $400M funding for the development of a bowel disease drug in partnership with Teva.

Controversies· May 9

Sanofi SA was among the companies held in a portfolio valued between $15,001 and $50,000 by an FDA executive who should have avoided such investments.
The FDA executive claimed they received bad advice from the agency's ethics office regarding their holdings in Sanofi and other companies.
Sanofi was one of several pharmaceutical companies whose stocks were owned by an FDA executive who was subject to conflict-of-interest bans.

Macro· Jan 6

Sanofi is mentioned as a pharmaceutical company that may be spared from economic sanctions, but Europe's investment in independence from the US could benefit European pharmaceutical companies like Sanofi.
Sanofi is listed among companies that could benefit from Europe's investment in independence from the US, including Novartis, Roche, Biontech, Bayer, and FMC.
The US invasion of Greenland and subsequent economic sanctions could impact oil companies, Boeing, Caterpillar, and GE, with pharmaceutical companies like Pfizer and Eli Lilly potentially being spared in the short-run.

Technical Analysis· Nov 1

$SNY is trading above its 200-day SMA, a key technical indicator, with a 6-month momentum of 46.85.
The stock has a low momentum of -3 and a 40-day near-low, with a second pivot at 7.
All technical factors (TFs) are showing a negative acceleration, with a 0.9% change in price and a large float of 2.2 billion.

Generated by AI

Community

Of the messages about SNY, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	9.52%	51.08%	76.15%	26.86%
Newcomers	90.48%	48.92%	23.85%	73.14%

Regulars· Jul 30

Sanofi's Dupixent has achieved remarkable YOY growth, with sales potential exceeding €25B in 2030, driven by the atopic dermatitis market and Th2 disease indications.
The new CEO is re-evaluating the pipeline, aiming for a more realistic view of Phase 3 go/no-go decisions, and is considering acquisitions in the range of $2-5B.
Analysts emphasize that the new CEO is moving towards rapid decision-making, and the company's valuation is considered low, making it an attractive acquisition target for other companies.

Newcomers· Jan 15

Sanofi is reportedly considering a new takeover offer for Oculis, after their initial $16/share bid was rejected in September.
The Oculis CEO has been quoted as saying that cultivating multiple bidders is part of a CEO's job, which may indicate that the company is open to negotiations.
Despite the initial bid being rejected, the Oculis stock price is currently below $11, suggesting that investors may see the potential for a higher offer.

Generated by AI

News

GSK vs. SNY: Which Europe-Based Pharma Stock Has More Potential?

Detailed price information for Sanofi-Aventis S.A. ADR (SNY-Q) from The Globe and Mail including charting and trades.

22h agoThe Globe and Mail

Sanofi's New Drugs Poised to Drive Growth Beyond Dupixent

SNY's new drugs are gaining momentum, with Altuviiio, Ayvakit and Sarclisa poised to broaden growth beyond Dupixent.

4d agoYahoo Finance

Sanofi Is Using AI Agents To Cut Through Enterprise App-Hopping

4d agoForbes

Why Is Sanofi (ENXTPA:SAN) Reshaping Its Business Around Vaccines And Mature Medicines?

Sanofi (ENXTPA:SAN) opened the Charles Best Building in Canada, described as the largest biomanufacturing investment in the country. The new Canadian site expands Sanofi's flu vaccine production capacity, with the goal of strengthening readiness for future influenza seasons. Sanofi agreed to transfer a portfolio of mature medicines and several manufacturing sites to Cheplapharm, while also taking an equity stake in the partner. The inauguration of the Charles Best Building and the broadened...

6d agoYahoo Finance

European drugmakers call for faster trials, more spending to compete with US, China

7d agoReuters

Sanofi Reviews Pipeline, Broadens Deal Hunt as It Rebuilds Research Engine

8d agoYahoo Finance

Also Discussed

Investors talking about SNY also mention

#	Name	Attention
1	Novartis AG Sponsored ADRNVS	0%-0.01
2	Regeneron Pharmaceuticals, Inc.REGN	0%-0.01
3	MannKind CorporationMNKD	0.02%+0.01
4	AstraZeneca PLC American Depositary SharesAZN	0.02%+0.02
5	TBIO - Telesis Bio, Inc.	——
6	Merck & Co., Inc.MRK	0.01%-0.06
7	Bristol-Myers Squibb CompanyBMY	0.01%0
8	Alnylam Pharmaceuticals, Inc.ALNY	0%0
9	BioMarin Pharmaceutical IncBMRN	0%+0
10	GSK plc ADRGSK	0%0

Sanofi ADR

Healthcare
Drug Manufacturers - General

Sanofi ADR is an American Depositary Receipt representing shares of Sanofi, a global healthcare company focused on pharmaceuticals and vaccines. Through its ADR program, U.S. investors can access the company’s ordinary shares in a form that is traded in the United States, while the underlying business remains centered in France. Sanofi develops, manufactures, and commercializes prescription medicines across several therapeutic areas, including specialty care, general medicines, and immunology, and it also operates a major vaccines business. The company serves patients, healthcare providers, and public health systems in markets around the world, with products used in chronic, rare, and infectious diseases. Sanofi ADR reflects the company’s broad role in the global biopharmaceutical market, combining research, production, and distribution capabilities with a diversified healthcare portfolio.

Website

Location

46, avenue de la Grande ArmEe

Paris, 75017

France

Social

What share of all stock conversation is about SNY?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% -0.01	0% +0	0% 0	0.01% 0

Aug 17

A financial analyst purchased Sanofi shares based on technical analysis, but now questions the decision after reevaluating the analysis.
A job posting at Sanofi (CIC) is announced, seeking a head for the COVID vaccine portfolio, including combination vaccines with Nuvaxovid.
The analyst's Sanofi graph is different when using dividend reinvestment, and they are asked why they choose not to include it.

Generated by AI

Sentiment

Of the messages about SNY that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	0% -100	92.17% -7.83	84.34% -11.46	83.09% +2.73
Bearish	100% new	7.83% new	15.66% +11.46	16.91% -2.73

Bullish· Jan 15

Sanofi is reportedly preparing a sweeter takeover offer for Ocular Therapeutix, which could lead to a higher price for the asset.
The asset's strong ophthalmology pipeline, including the AXPAXLI Ph3 data expected in Q1 2026, adds a significant catalyst layer to the potential takeover.
The expected takeover and strong pipeline make the asset's current price of under $11 a potential buying opportunity.

Bearish· Sep 4

$SNY's amlitelimab failed to meet expectations in its Phase 3 trial, with efficacy falling short of Dupixent's benchmark.
The disappointing trial results led to a significant drop in Sanofi's stock price, with investors questioning the company's pipeline post-2031 patent expiry.
The failure of amlitelimab raises concerns about Sanofi's ability to offset Dupixent's looming patent expiry, which could have a major impact on the company's sales and revenue.

Generated by AI

Topics

Of the messages about SNY that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	64.84%	64.67%	18.05%
Macro	—	33.59%	15.82%	37.26%
Earnings	—	0%	8.26%	1.24%
Technical Analysis	—	0%	0.7%	3.09%
Analysts	—	1.56%	10.54%	38.97%
Controversies	—	0%	0%	1.4%

Earnings· Oct 27

Sanofi reported Q3 earnings of $2.55 per share, missing the FactSet consensus of $1.30, and saw revenues fall 4.1% year/year to $11.96 billion.
The company reaffirmed guidance for FY23, seeing EPS growth in the mid single-digits, but warned that increased investments in R&D and a tax-rate change will cause 2024 earnings to fall from 2023 levels.
Sanofi's shares sank 17% after the earnings report, with the company also planning to spin off its consumer health division and bring it to the stock exchange.

Analysts· Apr 7

HSBC Securities downgraded Sanofi (SNY) to "Reduce" from "Hold".
Argus initiated coverage of Sanofi (SNY) with a "Buy" rating.
Raymond James Trust N.A. increased its stake in Sanofi (SNY).

Announcements· Mar 4

Sanofi has entered into an exclusive global licensing agreement with Sino Biopharmaceutical for the development, manufacturing, and commercialization of rovadicitinib, a dual JAK/ROCK inhibitor.
Sanofi will pay up to $1.53B for global rights to a first-in-class JAK/ROCK inhibitor from Sino Biopharmaceutical, with the asset already approved in China for myelofibrosis and in Phase 3 for cGVHD.
Sanofi has secured a $400M funding for the development of a bowel disease drug in partnership with Teva.

Controversies· May 9

Sanofi SA was among the companies held in a portfolio valued between $15,001 and $50,000 by an FDA executive who should have avoided such investments.
The FDA executive claimed they received bad advice from the agency's ethics office regarding their holdings in Sanofi and other companies.
Sanofi was one of several pharmaceutical companies whose stocks were owned by an FDA executive who was subject to conflict-of-interest bans.

Macro· Jan 6

Sanofi is mentioned as a pharmaceutical company that may be spared from economic sanctions, but Europe's investment in independence from the US could benefit European pharmaceutical companies like Sanofi.
Sanofi is listed among companies that could benefit from Europe's investment in independence from the US, including Novartis, Roche, Biontech, Bayer, and FMC.
The US invasion of Greenland and subsequent economic sanctions could impact oil companies, Boeing, Caterpillar, and GE, with pharmaceutical companies like Pfizer and Eli Lilly potentially being spared in the short-run.

Technical Analysis· Nov 1

$SNY is trading above its 200-day SMA, a key technical indicator, with a 6-month momentum of 46.85.
The stock has a low momentum of -3 and a 40-day near-low, with a second pivot at 7.
All technical factors (TFs) are showing a negative acceleration, with a 0.9% change in price and a large float of 2.2 billion.

Generated by AI

Community

Of the messages about SNY, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	9.52%	51.08%	76.15%	26.86%
Newcomers	90.48%	48.92%	23.85%	73.14%

Regulars· Jul 30

Sanofi's Dupixent has achieved remarkable YOY growth, with sales potential exceeding €25B in 2030, driven by the atopic dermatitis market and Th2 disease indications.
The new CEO is re-evaluating the pipeline, aiming for a more realistic view of Phase 3 go/no-go decisions, and is considering acquisitions in the range of $2-5B.
Analysts emphasize that the new CEO is moving towards rapid decision-making, and the company's valuation is considered low, making it an attractive acquisition target for other companies.

Newcomers· Jan 15

Sanofi is reportedly considering a new takeover offer for Oculis, after their initial $16/share bid was rejected in September.
The Oculis CEO has been quoted as saying that cultivating multiple bidders is part of a CEO's job, which may indicate that the company is open to negotiations.
Despite the initial bid being rejected, the Oculis stock price is currently below $11, suggesting that investors may see the potential for a higher offer.

Generated by AI

Sanofi

Social

Aug 17

Bullish· Jan 15

Bearish· Sep 4

Earnings· Oct 27

Analysts· Apr 7

Announcements· Mar 4

Controversies· May 9

Macro· Jan 6

Technical Analysis· Nov 1

Regulars· Jul 30

Newcomers· Jan 15

GSK vs. SNY: Which Europe-Based Pharma Stock Has More Potential?

Sanofi's New Drugs Poised to Drive Growth Beyond Dupixent

Sanofi Is Using AI Agents To Cut Through Enterprise App-Hopping

Why Is Sanofi (ENXTPA:SAN) Reshaping Its Business Around Vaccines And Mature Medicines?

European drugmakers call for faster trials, more spending to compete with US, China

Sanofi Reviews Pipeline, Broadens Deal Hunt as It Rebuilds Research Engine

Also Discussed

Sanofi ADR

Company Information

Location

GSK vs. SNY: Which Europe-Based Pharma Stock Has More Potential?

Sanofi's New Drugs Poised to Drive Growth Beyond Dupixent

Sanofi Is Using AI Agents To Cut Through Enterprise App-Hopping

Why Is Sanofi (ENXTPA:SAN) Reshaping Its Business Around Vaccines And Mature Medicines?

European drugmakers call for faster trials, more spending to compete with US, China

Sanofi Reviews Pipeline, Broadens Deal Hunt as It Rebuilds Research Engine

Also Discussed

Social

Aug 17

Bullish· Jan 15

Bearish· Sep 4

Earnings· Oct 27

Analysts· Apr 7

Announcements· Mar 4

Controversies· May 9

Macro· Jan 6

Technical Analysis· Nov 1

Regulars· Jul 30

Newcomers· Jan 15